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Abstract
Background: Solitary Fibrous Tumor (SFT) is a distinct soft tissue neoplasm associated with NAB2-STAT6 gene
fusion. It can involve a number of anatomic sites and exhibits a wide spectrum of histological features.
Main body: Apart from diversity in morphological features seen even in conventional SFT, two histologic variants
(fat-forming and giant cell-rich) are also recognized. In addition, a malignant form and dedifferentiation are well
recognized. Owing to diverse histological features and involvement of diverse anatomic locations, SFT can mimic
other soft tissue neoplasms of different lineages including schwannoma, spindle cell lipoma, dermatofibrosarcoma
protuberans, liposarcoma, gastrointestinal stromal tumor (GIST), malignant peripheral nerve sheath tumor (MPNST),
and synovial sarcoma. SFT is classified as an intermediate (rarely metastasizing) tumor according to World Health
Organization Classification of Tumors of Soft tissue and Bone, 5th edition. The management and prognosis of SFT
differs from its malignant mimics and correct diagnosis is therefore important. Although SFT expresses a distinct
immunohistochemical (IHC) profile, the classic histomorphological and IHC profile is not seen in all cases and
diagnosis can be challenging. NAB2-STAT6 gene fusion has recently emerged as a sensitive and specific molecular
marker and its IHC surrogate marker signal transducer and activator of transcription 6 (STAT6) has also shown
significant sensitivity and specificity. However, few recent studies have reported STAT6 expression in other soft
tissue neoplasms.
Conclusion: This review will focus on describing the diversity of histological features of SFT, differential diagnoses
and discussing the features helpful in distinguishing SFT from its histological mimics.
Keywords: Solitary fibrous tumor, Hemangiopericytoma, STAT-6, NAB2-STAT6, CD34, Staghorn, fusion transcript,
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Background
The morphological features of solitary fibrous tumor
(SFT) were originally described in 1931 by Klemperer and
Rabin in a series of 5 cases of pleural neoplasms [1]. Simi-
lar tumors were named “solitary (localized) mesothelioma
of pleura” by Stout and Murray in 1942 [2]. These tumors
were renamed “solitary fibrous tumor” by Stout and
Hamidi in 1951 [3]. The term “Hemangiopericytoma”
(HPC) was used for the first time by Stout and Murray in
1942 while describing a series of 9 cases [4]. The diagnos-
tic criteria for HPC were refined and features for assess-
ment of malignancy were established by Enzinger and
Smith in a large study of 106 cases [5]. Until 1990, SFT
was reported only in pleura and lung [6]. The first series
of extra-thoracic SFT was published in 1991 [7]. Even be-
fore the identification of a unifying molecular signature,
owing to their clinicopathological similarities, SFT and
HPC were considered to represent two ends of histomor-
phological spectrum of a single tumor entity [8, 9]. The
molecular hallmark of these tumors is the recurrent fusion
of NAB2 and STAT6 genes located at chromosomal re-
gion 12q13 [10–12]. These tumors were merged together
into a single entity in 4th edition of World Health
Organization (WHO) Classification of Tumors of Soft Tis-
sue and Bone [13]. Current WHO Classification of Soft
Tissue and Bone Tumors has classified SFT as a fibroblas-
tic neoplasm with intermediate (rarely metastasizing) be-
havior [14]. However, in the current WHO Classification
of Tumors of Central Nervous System, extrameningeal
SFT and HPC are described as a single group but different
histologic grades are assigned to these tumors while
retaining the names [15].
Main text
Clinical features
SFTs can occur in patients over a wide age range with
peak incidence in 5th and 6th decades of life. These tu-
mors are rare in children and adolescents [14, 16]. SFTs
have been reported at almost every anatomic site. Pleura
is the most common site and accounting for approxi-
mately 30% cases. Other frequently involved sites in-
clude meninges (27%), abdominal cavity (20%), trunk
(10%), extremities (8%) and head & neck (5%) [17].
Pleural SFTs present at somewhat older age (mean =
60.2 years) compared to meningeal (mean = 50.6 years)
and extra-pleural SFTs (mean = 50.3 years) [18]. No
known risk factors for development of SFTs are cur-
rently known [16]. SFTs are usually asymptomatic, slow
growing tumors which are often discovered as an inci-
dental finding on imaging [19]. These tumors sometimes
produce symptoms related to pressure effects on adja-
cent tissues/organs [14].
Tumor size can range from 1 to 40 cm with median size
of 5–8 cm [14, 19]. SFTs of head and neck are generally
smaller in size than the more slowly growing tumors of
abdominal cavity may reach larger size over a longer time
period before causing significant symptoms [14, 20]. SFTs
usually involve deep soft tissues but few tumors may occur
in superficial locations [21, 22]. Some SFTs present with
“Doege-Potter Syndrome”, a paraneoplastic hypoglycemic
syndrome resulting from excessive production of insulin-
like growth factor II (IGF2) [23, 24].
Gross features
Grossly, conventional SFTs are often well-circumscribed
and partially encapsulated with a multinodular, whitish,
firm cut surface (Fig. 1a). Myxoid change and hemorrhage
may be seen in some cases. Malignant and locally aggres-
sive tumors may show irregular infiltrative borders and
necrotic areas (Fig. 1b) [14, 17].
Histological features
Histologically, SFTs are variably cellular tumors com-
posed of ovoid to spindled cells exhibiting patternless
growth or a storiform pattern against a variably collage-
nous background stroma containing thin-walled large
branching, “staghorn”-shaped (HPC-like) blood vessels
(Fig. 2a&b). Medium sized blood vessels with perivascu-
lar fibrosis are also commonly seen (Fig. 2c) [17, 25].
The background stroma may show focal or diffuse myx-
oid change (Fig. 2d) [25–27]. Classic fibrous SFTs are
paucicellular tumors composed of spindle shaped cells
arranged in short wavy fascicles or haphazardly present
against prominent fibrous stroma with cracking artifact
and abundant keloid-type collagen (Fig. 3a&b). These
cells have uniform, elongated or fusiform nuclei and
scant cytoplasm. Cellular SFTs are more cellular and
composed of spindle shaped and rounded cells with
round to oval nuclei having condensed chromatin. Peri-
vascular fibrosis is frequently present. Gaping blood ves-
sels are more frequently seen at the periphery of tumors
(Fig. 3c&d). Markedly cellular tumors (still known as
HPCs in meninges) are composed of sheets of more
primitive-appearing rounded cells (Fig. 4a&b).
The vascular channels in SFT lack a connective tissue
layer and the endothelial cells merge with surrounding
tumor cells. Fibrotic background and perivascular fibro-
sis are not seen [20]. HPC-like vasculature can be seen
in other mesenchymal tumors including various soft tis-
sue sarcomas [5, 10]. This gave rise to a debate whether
HPC was a distinct tumor entity or simply a non-
specific histomorphological pattern seen in various
tumor types [28–30].
In comparison to pleural and extra-pleural tumors,
meningeal tumors are more frequently cellular and show
HPC type morphology [18]. SFTs generally show low
mitotic activity and lack significant nuclear pleomorph-
ism and/or necrosis [14].
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Some variants of SFTs show prominence of certain
unusual morphological features. These include fat-
forming, giant cell-rich and dedifferentiated variants
[17]. The fat-forming variant of SFT or lipomatous HPC
shows abundance of mature adipocytes in stroma (Fig.
4c). This variant usually involves deep soft tissues but
has been reported in orbit, neck, parotid gland, mediasti-
num, stomach, retroperitoneum, paratesticular soft tis-
sue and thigh [31–34]. The giant-cell variant of SFT
shows many multinucleated stromal giant cells usually
arranged around pseudovascular spaces (Fig. 4d). This
variant was previously known as giant cell angiofibroma
and most of these cases involved periorbital soft tissue.
However, it has also been reported in several extra-
orbital locations such as head and neck, retroperito-
neum, back, vulva, hip, and inguinal region [35–37].
Like other soft tissue tumors, dedifferentiation is also
observed in SFT. The dedifferentiated variant is ex-
tremely rare and shows abrupt transition to a low or
high-grade sarcoma with adjacent conventional SFT.
The dedifferentiated component is mostly in the form of
spindle cell sarcoma not otherwise specified or
Fig. 1 Gross appearance of SFT: a. Benign SFT appearing as a well-circumscribed, white and firm tumor. b. Malignant SFT of retroperitoneum
exhibiting ill-defined borders, variegated cut surface and cystic degeneration
Fig. 2 a. SFT exhibiting hypo and hypercellular areas of spindle cells against collagenous background stroma along with, b. HPC-like vessels, c.
stromal and perivascular fibrosis and, d. myxoid change in stroma
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Fig. 3 a. Classic SFT exhibiting cracking artifact and, b. abundant keloid-type collagen, c&d. Cellular SFT exhibiting increased cellularity, gaping
blood vessels and more darkly stained nuclei
Fig. 4 a. Markedly cellular tumor showing sheets of small sized cells with hyperchromasia, b. Tumor cells exhibiting round cell morphology, c.
Lipomatous SFT composed of mature adipocyte intermixed with tumor cells, d. Giant cell SFT exhibiting multinucleated giant cells focally lining
pseudovascular spaces
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undifferentiated pleomorphic sarcoma (Fig. 5a&b) and
can rarely show osteosarcomatous or rhabdomyosarco-
matous differentiation [38–43]. Dedifferentiation may be
seen in primary or recurrent tumors. It can be associated
with loss of expression of immunohistochemical markers
and newer molecular alterations. Occasional squamous
and neuroendocrine differentiation has also been re-
ported in SFTs [40].
Features suggestive of malignant behavior
Different clinical and histomorphological features have
been described which are suggestive of malignancy.
These features include older age, larger tumor size, in-
creased cellularity, increased mitotic activity (≥4/10HPFs
or > 2mitoses/2 mm2), nuclear pleomorphism, tumor ne-
crosis and infiltrative borders [5, 6, 14, 17, 20, 44–47].
Tumors lacking malignant histological features in pri-
mary resection specimens may acquire malignant fea-
tures at time of recurrence and metastases [47].
In extra-pleural and extra-meningeal tumors, Pasquali
et al. found hypercellularity, increased mitotic rate and
nuclear pleomorphism to be associated with recurrence
and hypercellularity and pleomorphism to be associated
with reduced overall survival [48]. Demicco et al. re-
ported patient age, tumor size and mitotic rate to be as-
sociated with time to metastasis and tumor related
death, and necrosis to be a predictor of metastasis [49].
Tumor size is usually considered to be a negative prog-
nostic factor but SFTs can grow to a large size without
behaving aggressively [14, 48]. Kim et al. assessed the
utility of different risk assessment systems in SFTs from
different sites and found mitotic rate (> 4/10 HPF) to be
the only independent prognostic factor [18]. Yamada
et al. identified dedifferentiation as a major adverse
prognostic factor and hypoglycemia, cerebromeningeal
and intra-abdominal locations to be associated with poor
prognosis [43].
TP53 immunohistochemical (IHC) expression has also
been found to be associated with recurrence and/or me-
tastasis [50]. In one study, TERT promoter mutations
were found to be predictors of metastasis-free survival in
intermediate risk category of SFT [51]. One of the latest
risk stratification models by Demicco et al. is based on
assessment of patient’s age, mitoses/mm2, tumor size
and percentage of tumor necrosis. It stratifies SFTs into
low, intermediate and high-risk categories and is more
accurate in predicting the prognosis [52].
Immunohistochemical features of SFT
A combination of CD34, CD99 and BCL-2 has been
widely used to diagnose SFT. These IHC markers are
sensitive and usually show diffuse and strong expression
in approximately 90% cases (Fig. 6a-c). However, these
markers have limited usefulness due to their expression
in other neoplasms closely mimicking SFT histologically
[21, 53]. CD34 expression has been observed in 81–95%
SFTs but its expression is lost especially in malignant
and dedifferentiated tumors [54–57]. BCL-2 is a more
sensitive marker (> 90% sensitivity) while CD99 is less
sensitive (~ 75% sensitivity). However, specificity of both
these markers is quite low [21, 53, 54, 58, 59].
STAT6 IHC stain has emerged as a useful surrogate
marker of NAB2-STAT6 gene fusion with excellent sen-
sitivity and specificity and is also expressed in malignant
cases (Fig. 6d) [55, 56, 60]. In a recent study, diffuse and
strong nuclear expression for STAT6 IHC marker was
observed in all 52 cases but gene fusion was detected by
reverse transcription polymerase chain reaction in 48
(92%) cases (RT-PCR) [20].
STAT6 IHC marker can also be expressed in some
other soft tissue neoplasms such as well differentiated
liposarcoma (WDL) or dedifferentiated liposarcoma
(DDL), desmoid fibromatosis, unclassifiable sarcoma,
neurofibroma, myxoid liposarcoma, undifferentiated
pleomorphic sarcoma, low grade fibromyxoid sarcoma,
Fig. 5 Dedifferentiated SFT; a. Abrupt transition of conventional SFT areas with high grade sarcomatous areas with, b. marked nuclear pleomorphism
and increased mitoses
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synovial sarcoma (SS) and ovarian fibroma [17, 61, 62].
Doyle et al. observed positive STAT6 expression in 4 out
of 35 (11%) cases of DDL [61]. In a large study, Demicco
et al. assessed STAT6 expression in 1781 non-SFT mes-
enchymal tumors and observed strong nuclear expres-
sion in 4% cases. Tumors which demonstrated positive
expression included unclassifiable sarcoma (8/65{12%}),
WDL and DDL (49/409{12%}), desmoid tumor/fibroma-
tosis (14/184{8%}), neurofibroma (3/60 {5%}), clear cell
sarcoma (1/19{5%}), myxoid liposarcoma (2/108{2%})
and undifferentiated pleomorphic sarcoma (2/173{1%}).
Ouladan et al. evaluated STAT6 expression in 374 non-
SFT mesenchymal tumors and positive nuclear staining
was observed in only 4 (1%) cases including 2 cases of
WDL, 1 case of DDL and 1 case of SS [63]. STAT6 ex-
pression was also found in a small subset of non-
neoplastic tissue including scar tissue and adipose tissue
[62]. In a series of prostatic SFT and smooth muscle tu-
mors of uncertain malignant potential (STUMP), the
sensitivity and specificity of STAT6 for SFT was 91 and
75% respectively [64]. The expression of STAT6 in SFT
is exclusively nuclear but other tumors may show both
nuclear and cytoplasmic staining [62].
Gene expression profiling studies have also identified
overexpression of GRIA2 gene and aberrant expression of
GRIA2 protein in SFT [12]. This protein is usually
expressed in central nervous system tissue and epithelia of
some organs but can also be expressed in soft tissue tu-
mors such as SFT and dermatofibrosarcoma protuberans
(DFSP) [54]. In one study, overall frequency of GRIA2
IHC expression in SFT was 80%. The frequency was 86%
in malignant cases and 100% in dedifferentiated cases [17].
Another study found aldehyde dehydrogenase 1
(ALDH1) to be a useful marker for SFT. It was
expressed in 76% cases, and along with STAT6 expres-
sion, was found be a useful marker for distinguishing
SFT from its soft tissue mimics [63]. ALDH1 was also
found to be helpful in differentiating meningeal SFT
from meningioma and SS [57].
Some cases of pleural and abdominal SFT may show
multifocal expression of cytokeratins [65]. Few cases of
SFT may also show focal expression for epithelial mem-
brane antigen (EMA), alpha smooth muscle actin
(ASMA), beta catenin, glial fibrillary acidic protein
(GFAP) and neuron-specific enolase (NSE). Conversely,
expression of h-caldesmon, desmin, CD31 and S100 is
almost always negative [65]. TP53 IHC expression is ob-
served in malignant cases [50].
Differential diagnosis
Owing to diversity of histological patterns exhibited by
SFT, Machado et al. termed SFT “the great simulator” of
soft tissue tumors [25]. SFTs often pose diagnostic chal-
lenge and integration of clinical, histomorphological, im-
munohistochemical and molecular features is necessary
for establishing correct diagnosis [17]. In extra-pleural
locations, the pathologist must rule out tumors which
are more common in those particular sites [17].
Fig. 6 Tumor cells showing positive staining for, a. CD34, b. CD99, c. BCL2 and, d. nuclear staining for STAT6 IHC stains
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Comparison of clinical, histomorphological, immunohis-
tochemical and molecular features of SFT with some of
the tumors important in differential diagnosis is summa-
rized in Table 1.
Monophasic and poorly differentiated SSs mimic SFTs
owing to sheet-like growth pattern, spindle to ovoid cell
morphology, HPC-like vasculature in some cases and CD99
and BCL-2 expression [14]. Occasional cases may also show
positivity for STAT6 [61, 62]. However, CD34 expression is
almost always absent in SS. Some cases of SFT may also
show weak expression of TLE1. However, strong and diffuse
nuclear expression of TLE1 favors the diagnosis of SS. Mo-
lecular studies for translocation t(X;18) are recommended
for confirmation of diagnosis [14, 66].
Malignant peripheral nerve sheath tumor (MPNST) is
composed of cellular sheets of spindle cells which may al-
ternate with hypocellular areas. Tumor cells may show
HPC-like vasculature and accentuation around blood ves-
sels. Some cases of low grade MPNST may also demon-
strate positive expression for CD34. Majority of MPNSTs
show typical “nerve sheath morphology” at least focally.
Loss of H3K27me3, STAT6 negativity and expression of
SOX-10, S100 or GFAP favors MPNST [21, 66].
Primary intrapulmonary SFTs are uncommon tumors
which need to be differentiated from a number of mes-
enchymal, epithelial and mixed tumors. Intrapulmonary
SFTs especially need to be distinguished from sarcoma-
toid carcinoma. Squamous cell carcinoma, carcinoid
tumor and malignant mesothelioma (originating from
pleura) may also show spindle cell morphology and
mimic SFT [24]. Multifocal expression for cytokeratins,
observed in some pleural and abdominal SFTs, can be
misleading as two important differential diagnoses in
these locations (sarcomatoid carcinoma and mesotheli-
oma) also show similar staining pattern [65]. Other mes-
enchymal intrapulmonary tumors such as inflammatory
myofibroblastic tumor (IMT), leiomyosarcoma, leio-
myoma, and adenofibroma should also be considered in
the differential diagnosis (DD). Positive expression for
CD34 and STAT6 IHC stains helps in establishing the
diagnosis of SFT [24, 61, 62].
Fat-forming or lipomatous SFT can resemble benign li-
pomatous tumors such as spindle cell lipoma (SCL) or
malignant lipomatous tumors such as WDL or DDL.
Spindle cell lipoma exhibits bland spindle cells, ropy colla-
gen bundles and mature adipose tissue and expresses
CD34 immunostain. All these features are seen to a vari-
able degree in lipomatous SFT. However, STAT6 expres-
sion is not observed in SCL. RB1 gene loss by fluorescence
in situ hybridization (FISH) is also observed in SCL.
DDLs exhibit a wide variety of histological features which
resemble low- and high-grade sarcomas. In retroperitoneal
location especially, DDL can resemble malignant fat-forming
SFT. The situation is further complicated by STAT6 nuclear
expression in DDL. Mouse double minute 2 (MDM2) gene
amplification and diffuse nuclear IHC expression in DDL is
extremely helpful in this situation because of 100% specificity
and 97.2% sensitivity. CDK4 and p16 are also useful IHC
markers for the diagnosis of WDL and DDL [31–34, 61, 66,
67, 69, 71–73].
Cellular schwannomas can also resemble SFT as these
are composed of fascicles of bland spindle shape cells
against a collagenous background and frequently exhibit
thick-walled and hyalinized blood vessels. Some cases
may show CD34 expression. Presence of thick fibrous
capsule, foamy macrophages, lymphoid infiltrate, wavy
nuclei with tapered ends and S100 expression favors the
diagnosis of schwannoma [66].
Angiofibroma of soft tissue is a circumscribed tumor
composed of bland spindle cells against variably collage-
nous to myxoid background stroma containing a rich
network of thin-walled blood vessels. Tumor cells are
variably positive for CD34, EMA and Desmin. STAT6
expression is typically negative. The molecular signature
of this tumor is translocation t(5;8) (p15;q13) resulting
in AHRR-NCOA2 fusion gene [68].
Myofibromas are biphasic tumors occurring in young
age which can resemble SFT due to pericytic growth pat-
tern and presence of HPC-like vasculature. These tumors
variably express CD34 and ASMA. Presence of myoid
nodules at the periphery of the tumor is unique to myofi-
broma and provides a useful diagnostic clue [70].
Myofibroblastomas are circumscribed tumors com-
posed of intersecting fascicles of bland spindle shaped
myofibroblastic cells with intervening collagen bundles
and occasional mature adipocytes. Tumor cells demon-
strate positivity for CD34, Desmin and ASMA IHC
stains. These tumors also show RB1 gene loss by FISH
which is not observed in SFT [71].
Cellular angiofibroma is another well circumscribed,
multilobulated tumor composed of spindle cells against
a collagenous and edematous background stroma con-
taining small to medium sized thick walled and hyali-
nized blood vessels. Some cases also show mature
adipocytes and collagen bundles. Variable expression for
CD34, ASMA and Desmin may be seen. RB1 gene loss is
also observed [71].
Deep fibrous histiocytoma also exhibits intersecting
fascicles or storiform pattern of bland spindle cells. Stro-
mal hyalinization and HPC-like vessels are also seen.
Tumor cells may show positive expression for CD34 and
ASMA but STAT6 is negative [21].
In superficial locations, two soft tissue tumors with
CD34 expression need to be distinguished from SFT
[22]. These tumors are DFSP and superficial CD34 posi-
tive fibroblastic tumor (SCD34PFD). DFSP is a dermal
based tumor usually composed of fairly uniform spindle
cells with elongated nuclei arranged in storiform pattern
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Table 1 Differential Diagnosis of Solitary Fibrous Tumor
Age (years) M:F
ratio




40 to 70 Equal Pleura
Meninges; CNS & spinal
cord







Patternless spindled to ovoid cells
within a variably collagenous
















1.2:1 Most often deep soft
tissues of extremities or
limb girdles, distal
extremities (fingers, hand
foot), Head and & Neck
Fascicles & sheets of uniform
spindle cells. May have a
herringbone pattern. HPC like
branching vessels are common.











Equal Trunk and extremities,
followed by the head and
neck area
Hypercellular & hypocellular
fascicles of spindle-shaped cells
(marbleized pattern), perivascular
accentuation, HPC-like vascular
pattern, increase mitoses, geo-
graphic necrosis, heterologous dif-





















spermatic cord and (more
rarely) mediastinum, head
and neck, and trunk.
Fascicles or sheets of atypical












22:1 Pleura, Peritoneum Fascicles or haphazardly
distributed atypical spindle cells
with increase mitoses. Densely
collagenized stroma with
















Variably myxoid to collagenous
stroma, branching capillary
network & uniform bland spindle







40–60 10:1 Subcutis of posterior neck,
upper back & shoulders
Face, scalp, orbit, oral
cavity & extremities rarely
involved
Short fascicles of bland spindle
cells with short stubby nuclei,
variable number of adipocytes,
and ropy collagen bundles.










Skin & subcutis of
extremities, head & neck &
trunk.
Infantile cases involve
liver, heart, GIT, brain &
bone
Distinctive biphasic pattern with
nodules comprising of immature
spindle cells in center with HPC-
like vasculature and whorls of















Short fascicles of spindle cells with
short stubby nuclei, interspersed
broad collagen bands & variable















intersecting fascicles of spindle
cells containing stubby nuclei.
Scattered medium sized hyalinized
vessels. Wispy stromal collagen













head and neck region
Uniformly cellular storiform to
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and infiltrating into the subcutaneous adipose tissue.
SCD34PFD is also a dermal based tumor comprising of
sheets and fascicles of spindle to epithelioid cells. Tumor
cells have moderate cytoplasm and may show moderate
to marked atypia [74]. In comparison to these tumors,
SFTs have relatively more defined borders and heteroge-
neous cellularity. Molecular studies on DFSP typically
show translocation t(17;22) and/or supernumerary ring
chromosome r(17;22) [75].
In abdominal (and less commonly extra-abdominal)
locations, one important lesion which should be consid-
ered in the DD is low grade gastrointestinal stromal
tumor (GIST) which often shows spindle to ovoid cells
arranged in fascicles or randomly distributed. In
addition, CD34 expression is shared by GISTs and SFTs.
However, majority of GISTs are positive for CD117 and
DOG1 while STAT6 is always negative [14].
In meninges, meningothelial meningioma can be easily
distinguished from SFT by epithelioid cell morphology,
whorling, syncytial pattern and psammomatous calcifica-
tions [76]. Fibrous meningioma can resemble SFT due
to spindle cell morphology and vague fascicular pattern.
Atypical and anaplastic meningioma can mimic malig-
nant SFT due to presence of patternless/sheet-like
growth, necrosis, frequent mitoses, nucleolar promin-
ence, nuclear pleomorphism and small cell change. Men-
ingiomas usually express positivity for EMA and
progesterone receptor (PR). This expression is either
completely or partially lost in atypical and anaplastic
cases. However, all types of meningioma are negative for
CD34 and STAT6 IHC stains [76]. Therefore, a panel of
these IHC stains should be applied in meningeal tumors
when SFT is considered in the DD [77].
In hypercellular SFTs, tumor cells usually acquire
round cell morphology and mimic small round cell sar-
comas such as Ewing sarcoma (ES), rhabdomyosarcoma
and mesenchymal chondrosarcoma (MC) [25]. Due to
high incidence of rhabdomyosarcoma in young patients
with head and neck tumors, it should be kept in the dif-
ferential diagnosis. Presence of cambium layer and
rhabdomyoblastic differentiation along with absence of
HPC-like vasculature are useful clues in favor of rhabdo-
myosarcoma. In addition, myogenic markers like
MyoD1, myogenin and desmin are highly sensitive and
specific markers for rhabdomyosarcoma and are usually
not expressed in SFT [21, 78, 79].
The round cell population of mesenchymal chondro-
sarcoma also shows background HPC-like vasculature
which may be indistinguishable from SFT on morph-
ology. This raises a diagnostic challenge if chondroid
component is not sampled in small biopsy specimens.
Both ES and MC like SFT express CD99. Positivity for
NKX2.2 which is a recently introduced sensitive and
specific IHC marker for ES and expression of CD34 and
STAT6 by SFTs help in reaching the correct diagnosis
[21, 25].
Myxoid change in SFT is well reported and a number
of other soft tissue tumors with myxoid features must be
excluded. These tumors include low grade myxofibrosar-
coma, low grade fibromyxoid sarcoma and myxoid lipo-
sarcoma [25–27, 55, 60, 80, 81]. Some of these tumors
may express CD34 and occasional cases with STAT6 ex-
pression have also been reported. Careful examination of
tumor for cases showing conventional SFT morphology
along with diffuse and strong nuclear STAT6 expression
leads to accurate diagnosis [61, 62].
Soft tissue tumors with epithelioid morphology such
as epithelioid sarcoma and epithelioid angiosarcoma
sometimes need to be considered in the DD [25]. SFT
with giant cells is a rare occurrence and the DD of this
morphological form include soft tissue sarcomas with
giant cell component and nodular fasciitis [25, 82].
Prostatic stromal tumors of uncertain malignant po-
tential (STUMP) and prostatic stromal sarcoma (PSS)
can pose diagnostic problems for pathologists. STUMP
exhibits haphazard fascicles of spindle cells which do
not exhibit significant nuclear atypia or mitoses. How-
ever, PSS exhibits solid growth of spindle to epithelioid
cells with nuclear atypia, increased mitoses and necrosis.
However, these demonstrate a more regular pattern
Table 1 Differential Diagnosis of Solitary Fibrous Tumor (Continued)
Age (years) M:F
ratio
Sites Histological features IHC Key genetic
alterations









neck region, genital area,
the breast, and at acral
sites
Dermal uniform spindle cells
arranged in storiform, whorls &












composed of Antoni A areas with
interlacing fascicles of spindle cells
having tapered nuclei. Hyalinized
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histologically, lack HPC-like vasculature and collagen
deposition [55, 83]. Some of these tumors may express
positivity for CD34 and some of the prostatic SFTs may
also express PR [83]. However, STUMP and PSS lack
nuclear expression for STAT6. Combined specificity of
STAT6 and ALDH1 is 100% for SFTs of this region [55].
Molecular alterations in SFT
A number of studies have identified recurrent fusion of
two genes in majority of SFTs by next generation se-
quencing (NGS) and RT-PCR techniques. This gene fu-
sion is considered to be an initial event in the
tumorigenesis of SFT [12, 20]. These two genes, NGFI-A
binding protein 2 (NAB2) and STAT6 are located very
close to each other on chromosome 12 [10–12]. There-
fore, their fusion is difficult to detect by FISH technique
[12]. In a study conducted by Barthelme et al., diffuse
and strong nuclear IHC expression for STAT6 was ob-
served in 100% cases while gene fusion was detected in
92% cases by RT-PCR. Lack of gene fusion detection
was not related to technical issues in RNA isolation from
formalin fixed tissue [20].
NAB2 is a transcriptional repressor while STAT6 is a
transcription factor. Both proteins play important roles
in regulation of inflammation, fibroblastic activation,
collagen formation and vessel formation [84, 85]. These
proteins affect early growth response 1 (EGR1) tran-
scription factor which is an important regulator of fibro-
sis and wound healing in opposing manner [85–87].
NAB2 gene possesses 7 exons while STAT6 gene pos-
sesses 23 exons. As a result, a number of fusion variants
are generated with variable frequencies [10–12].
In a study of 52 pleural and extra-pleural tumors, 12
fusion variants were identified by multiplex RT-PCR in
48 (92%) cases. Three fusion variants were more fre-
quent and accounted for 75% of all fusion variants. Fu-
sion variants were grouped according to their potential
functional effects among the predicted chimeric pro-
teins. These fusion categories significantly correlated
with patient age, tumor size, mitotic activity, anatomic
site, histomorphological classification and clinical follow
up. Majority of the tumors harboring NAB2ex4-
STAT6ex2/3 gene fusion variant involved thoracic cavity
and showed classic fibrous SFT morphology. When
compared with tumors having other fusion variants,
these tumors had higher tumor age, larger tumor size,
lower mitotic activity and lower recurrence rate. Major-
ity of the tumor harboring NAB2ex6-STAT6ex16 and
NAB2ex6-STAT6ex17 fusion variants were deep seated
and involved extra-thoracic sites. These tumors occurred
in significantly younger age group, were smaller in size,
showed higher mitotic activity, cellular SFT or typical
HPC type morphology and higher recurrence rate [20].
Robinson et al. also found that majority of the tumors
with gene fusion variant NAB2ex6-STAT6ex16/17 were
extra-thoracic in location while two out of three tumors
with NAB2ex4-STAT6ex2/3 gene fusion variant were
seen in pleuropulmonary location [10]. In a study by
Chmielecki et al., majority of the tumors with NAB2ex4-
STAT6ex2 gene fusion variant involved lung or pleura.
NAB2ex6-STAT6ex16/17 gene fusion variant was not
detected [11]. Mohajeri et al. observed that the majority
of tumors with NAB2ex6-STAT6ex16/17 gene fusion
variants were located in extra-thoracic regions while half
of the tumors with NAB2ex4-STAT6ex2 gene fusion
variant involved pleuropulmonary region [12]. Yamada
et al. and Park et al. did not find any direct association
of gene fusion variants with malignancy. However, they
observed that the association between gene fusion vari-
ants and tumor location could indirectly affect the bio-
logical behavior of SFT [43, 50].
TERT promoter mutations were found to be associ-
ated with malignant SFTs in two studies [50, 51]. A
comprehensive genetic analysis in that study also re-
vealed down regulation of target genes of EGR1 [12].
Overexpression of genes encoding stem cell markers
such as ALDH1 has also been demonstrated. ALDH1
has been related to poor prognosis in breast carcinoma.
In addition, a number of growth factors and kinases are
overexpressed in SFTs. These include PDGFα, PDGFβ,
PDGFR-α, PDGFR-β, IGF1R, EGFR, VEGF, IGF2, c-Met,
c-kit, c-erbB2, PTEN, phosphorylated (p) AKT, pS6,
p4EBPEGFR, ERBB2, FGFR1, and JAK2 [88]. Overex-
pression of these markers leads to activation of Akt/
mTOR pathway and appears to be associated with tumor
necrosis [89]. Targeting Akt/mTOR pathway and IGF
signaling pathway might prove beneficial for irresectable
tumors [89]. PDGFR-α is more frequently expressed in
malignant SFTs compared to more localized tumors
[90]. A number of studies have also reported complete
loss or partial deletion of chromosomes 1,6,9,13,15,17,
18, X and gain of chromosomes 5,8,13,21 [91–94]. In a
recent study, TP53 mutations were identified in 41% ma-
lignant SFTs [50]. Dedifferentiated SFTs also character-
istically show TP53 mutations [25, 41–43, 95].
Follow up and prognosis
In one study, malignant SFTs were related with higher
rate of local recurrence and distant metastasis [96]. In
another study, tumors with malignant histological fea-
tures demonstrated indolent behavior while tumors lack-
ing malignant histological features behaved aggressively
[44, 47]. Extrathoracic site is an independent predictor
of poor prognosis. Tumors located in meninges, pelvis,
retroperitoneum and mediastinum are associated with
greater risk of recurrence [46]. Despite surgical excision
with clear margins, local recurrence and distant
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metastasis can occur in some cases [13]. In one study,
local recurrence was observed in 13 (39.3%) out of 39
cases [20]. Distant metastasis is a predictor of poor prog-
nosis and 75% patients with metastasis die of their dis-
ease [97]. In a study of extra-thoracic SFTs, median
overall survival duration ranged from 59 to 94months
and 5-year and 10-year survival rates were 89 and 73%
respectively [49].
Treatment
Wide surgical excision is the mainstay of treatment and
adjuvant radiotherapy and chemotherapy are not re-
quired in routine cases [98]. However, adjuvant radio-
therapy has been suggested to improve the local control
of tumor [99]. In meningeal tumors, SFTs (WHO grade
1) are treated with surgery alone while HPCs (WHO
grades 2 & 3) benefit from adjuvant radiotherapy [15].
Due to their rarity and lack of randomized control trials,
there is no global consensus on treatment of SFTs. A
multidisciplinary team approach is recommended for
treatment and management of these tumors [19].
Conclusions
Accurate diagnosis is essential for appropriate treatment
and management of SFTs. NAB2-STAT6 gene fusion
and its IHC expression are consistently observed in these
tumors. Immunohistochemistry is the most sensitive and
specific means of diagnosing SFT and is practical and
economical as well. Molecular studies require expensive
equipment and well-trained staff which reduces their
practicality and feasibility in resource limited laborator-
ies of developing countries. Molecular testing may be
helpful where IHC results are ambiguous. Thorough
knowledge about the morphological variations of SFTs
and correlation with clinical, IHC and molecular features
are helpful in avoiding misdiagnosis.
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